Corticosteroid-induced ocular hypertension and glaucoma: A brief review and update of the literature

Current Opinion in Ophthalmology

Volumn 17, Issue 2, 2006, Pages 163-167

  Jones III, Relief ^a   Rhee, Douglas J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Intravitreal triamcinolone; Ocular hypertension; Review; Steroid induced glaucoma

Indexed keywords

ACETIC ACID; ANTIGLAUCOMA AGENT; BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; DEXAMETHASONE ACETATE; HYDROCORTISONE; MEDRYSONE; MYOCILIN; PREDNISOLONE ACETATE; TRIAMCINOLONE ACETONIDE;

AQUEOUS HUMOR OUTFLOW; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DISEASE PREDISPOSITION; EXTRACELLULAR MATRIX; FAMILY HISTORY; GLAUCOMA; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR HYPERTENSION; MEDICAL LITERATURE; OPEN ANGLE GLAUCOMA; PATHOPHYSIOLOGY; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRABECULAR MESHWORK; TREATMENT PLANNING; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 33646940683     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Bernstein HN, Mills DW, Becker B. Steroid-induced elevation of intraocular pressure. Arch Ophthalmol 1977; 9:1075-1080.
2. Garbe E, Lorier J, Boivin JF, Siussa S. Inhaled and nasal glucocorticoids and the risk of ocular hypertension or open-angle glaucoma. JAMA 1997; 277:722-727.
3. Cubey RB. Glaucoma following the application of corticosteroids to the skin of the eyelids. Br J Dermatol 1976; 95:207-208.
4. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Exp Ophthalmol 2004; 32:656-657.
5. Kalina RE. Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol 1969; 81:78-90.
6. Behbehani AH, Owayed AF, Hijazi ZM, et al. Cataract and ocular hypertension in children on inhaled corticosteroid therapy. J Red Ophthalmol Strabismus 2005; 42:23-27.
7. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138:740-743. This article determined the prevalence of IOP elevation following intravitreal triamcinolone injection in patients with and without glaucoma. It allows the clinician to anticipate the elevated IOP approximately 100 days after injection.
8. Singh IP, Ahmad SI, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004; 138:286-287. This case series emphasized the possibility for an early and rapid increase in IOP after intravitreal glucocorticoid injection. Each of the patients in this case series needed surgery to manage the elevated IOP, and this fact underscores the importance of knowing the patient's past medical and ocular history and the importance of close follow-up. This is in stark contrast to most IVTA-associated glaucomas, which are primarily able to be managed medically.
9. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004; 122:336-340.
10. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. Invest Ophthalmol Vis Sci 1965; 4:187-197.
11. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol Vis Sci 1965; 4:198-205.
12. McLean JM. Use of ACTH and cortisone. Trans Am Ophthalmol Soc 1950; 48:293-296.
13. Francois J. Cortisone et tension oculaire. Ann D'Oculist 1954; 187:805.
14. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963; 70:482-491.
15. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone on the glaucomatous eye. Arch Ophthalmol 1963; 70:492-499.
16. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963; 70:500-507.
17. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965; 26:198-205.
18. Becker B, Hahn KA. Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol 1964; 54:543-551.
19. Davies TG. Tonographic survey of the close relatives of patients with chronic simple glaucoma. Br J Ophthalmol 1968; 52:32-39.
20. Gatson H, Absolon MJ, Thurtle OA, Sattar MA. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983; 67:487-490.
21. Becker B. Diabetes mellitus and primary open-angle glaucoma. Am J Ophthalmol 1971; 71:1-16.
22. Podos SM, Becker B, Morton WR. High myopia and primary open-angle glaucoma. Am J Ophthalmol 1966; 62:1038-1043.
23. Spaeth GL. Traumatic hyphaema, angle recession, dexamethasone hypertension, and glaucoma. Arch Ophthalmol 1967; 78:714-721.
24. Lam DSC, Fan DSP, Ng JSK, et al. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. Clin Exp Ophthalmol 2005; 33:252-258. This study investigated the ocular hypertensive and anti-inflammatory responses to two different dosage schedules of 0.1% topical dexamethasone. The authors showed that the ocular hypertensive effect of topical 0.1% dexamethasone is dose and age dependent in children. Children 6 years and under were at especially high risk. This becomes clinically relevant, especially when treating children with uveitis and other conditions that necessitate the use of corticosteroids. Most studies investigating steroid-induced glaucoma examined an elderly patient population.
25. Cantrill HL, Palmberg P, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol 1975; 79:1012-1017.
26. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003; 87:24-27.
27. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003; 43:386-390.
28. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999; 27:431-432.
29. Jonas JB, Degenrigh RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112:593-598. This study investigated the IOP response after IVTA injections and found that, when 25 mg of triamcinolone acetonide is used intravitreally, an IOP elevation can develop in about 50% of eyes. This was similar to that reported in [7]. For patients receiving this higher dose of IVTA, IOP elevation was noted about 1-2 months after the injection (slightly less than the 100 days reported in [7]). Likewise, IOP was normalized by topical medications in the vast majority of patients and returned to normal values without further medication about 6 months after the injection.
30. Clark AF, Wilson K, McCartney MD, et al. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1994; 35:281-294.
31. Clark AF, Brotchie D, Read AT, et al. Dexamethasone Alters F-actin architecture and promotes cross-linked actin network formation in human trabecular meshwork tissue. Cell Motil Cytoskeleton 2005; 60:83-95.
32. Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res 1993; 12:783-793.
33. Yue BYJT. The extracellular matrix and its modulation in the trabecular meshwork. Surv Ophthalmol 1996; 40:379-390.
34. Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci 1990; 31:2568-2571.
35. Alward WLM. The genetics of open-angle glaucoma: the story of GLC1A and myocilin. Eye 2000; 14:429-436.
36. Alward WLM, Finger JH, Coote MA, et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl J Med 1998; 338:1022-1027.
37. Tamm ER. Myocilin and glaucoma: facts and ideas. Prog Retina Eye Res 2002; 21:395-428.
38. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retina Eye Res 1999; 18:629-667.
39. Snyder RW, Stamer WD, Kramer TR, Seftor REB. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res 1993; 57:461-468.
40. Weinreb RN, Mitchell MD, Polansky JR. Prostaglandin production by human trabecular meshwork cells: in vitro inhibition by dexamethasone. Invest Ophthalmol Vis Sci 1983; 24:1541-1545.
41. Shirato S, Bloom E, Polansky J, et al. Phagocytic properties of confluent human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1988; 29:S125.
42. Weinreb RN, Polansky JR, Kramer SG, Baxter JD. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci 1985; 26:170-175.
43. Jonas JB, Kreissig I, Degenring R. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol 2003; 121:729-730.
44. Vendantham V. Intraocular pressure rise after intravitreal triamcinolone. Am J Ophthalmol 2004; 138:286-287.
45. Agrawal S, Agrawal J, Agrawal T. Management of intractable glaucoma following intravitreal triamcinolone acetonide. Am J Ophthalmol 2004; 138:286-287.